Treace Medical Concepts, Inc. filings document the regulatory disclosures of a medical technology company focused on devices for bunion and related midfoot surgery. Its 8-K reports cover operating results, preliminary unaudited financial information, Regulation FD investor materials, press-release exhibits and Inline XBRL cover data.
The company’s SEC record also includes disclosures on material financing arrangements, including term loan and revolving loan agreements, as well as officer departures, board changes and committee matters. Proxy materials address annual meeting procedures, director elections, executive compensation, equity awards and corporate governance for the Delaware corporation.
Treace Medical Concepts' Chief Innovation Officer, Sean F. Scanlan, exercised stock options and received common shares. On February 10, 2026, a stock option for 16,875 shares with a $1.05 exercise price was exercised, converting into 16,875 shares of common stock. Following this transaction, Scanlan directly beneficially owned 706,474 shares of common stock, which includes 511,291 restricted stock units.
William Blair Investment Management, LLC filed an amended Schedule 13G reporting its beneficial ownership of 1,145,498 shares of Treace Medical Concepts, Inc. common stock, representing 1.8% of the class as of the triggering date.
The firm has sole voting power over 879,228 shares and sole dispositive power over all 1,145,498 shares, with no shared voting or dispositive power. It certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Treace Medical Concepts.
Treace Medical Concepts, Inc. reported an equity award to its Chief Commercial Officer, Gaetano Guglielmino. On January 22, 2026, he was granted 150,000 restricted stock units (RSUs) of common stock at a price of $0 per share. Each RSU converts into one share of common stock as it vests. The RSUs vest in four equal annual installments, starting on January 22, 2027 and ending on January 22, 2030, conditioned on his continued service with the company. Following this grant, he beneficially owns 490,901 shares of common stock, including 422,250 RSUs.
Treace Medical Concepts Chief Legal & Compliance Officer Scot Michael Elder reported equity compensation and related share movements. On January 22, 2026, he disposed of 9,451 shares of Common Stock in a transaction coded "F" at a price of $0 per share, leaving him with 534,286 shares beneficially owned immediately after that line item. The same day, he acquired 262,500 shares of Common Stock in a transaction coded "A" at $0 per share, reported as restricted stock units.
The footnotes explain that these 262,500 RSUs each convert into one share of Common Stock upon vesting and vest in equal annual installments over four years, from January 22, 2027 through January 22, 2030, subject to continued service. After the reported transactions, Elder is shown as beneficially owning 796,786 shares, which includes 641,470 restricted stock units.
Treace Medical Concepts' Chief Financial Officer Mark Hair reported equity compensation activity in company stock. On January 22, 2026, he disposed of 17,037 shares of Common Stock at a stated price of $0, leaving him with 493,208 shares directly owned after that transaction, which included 351,134 restricted stock units.
On the same date, he was awarded 375,000 restricted stock units (RSUs) for which he is entitled to receive one share of Common Stock per RSU upon vesting at no cost. These RSUs vest in equal annual installments over four years, from January 22, 2027 through January 22, 2030, subject to his continued service. Following this grant, he directly beneficially owned 868,208 shares, which included 726,134 restricted stock units.
Treace Medical Concepts Chief Innovation Officer Sean F. Scanlan reported equity transactions in company stock. On January 21, 2026, he exercised a stock option for 53,500 shares of Common Stock at an exercise price of $0.72 per share, converting a previously held option into directly owned shares. On January 22, 2026, he received a grant of 262,500 restricted stock units (RSUs), each RSU representing one future share of Common Stock upon vesting. The RSUs vest in equal annual installments over four years from January 22, 2027 through January 22, 2030, contingent on his continued service with the company.
Treace Medical Concepts, Inc. Chief Executive Officer John T. Treace, who is also a director and 10% owner, reported equity award activity in company common stock on January 22, 2026.
One transaction disposed of 14,254 shares of common stock at $0 per share, and another transaction added 250,000 restricted stock units (RSUs) at $0 per share. After these transactions, he directly beneficially owned 7,011,633 shares of common stock, which, according to the footnotes, include 571,871 RSUs.
The 250,000 RSUs vest in equal annual installments over four years, with vesting dates on January 22, 2027 through January 22, 2030, contingent on his continued service. Additional shares are held by his spouse and in related trusts, and he disclaims beneficial ownership of those holdings.
Treace Medical Concepts, Inc. Chief Financial Officer reports an insider stock transaction. On 01/10/2026, Mark Hair reported an "F" code transaction involving 8,719 shares of common stock at a reported price of $0 per share. Following this transaction, he beneficially owned 510,245 shares of Treace Medical Concepts common stock in direct form. A noted portion of this position consists of 398,009 restricted stock units, which typically represent share-based awards that may settle in stock over time.
Treace Medical Concepts, Inc. officer Elder Scot Michael, Chief Legal & Compliance Officer and Corporate Secretary, reported a transaction in company common stock dated 01/10/2026. A transaction coded "F" involved 4,544 shares at a reported price of $0 per share, after which he beneficially owned 543,737 common shares. This beneficial ownership figure includes 410,845 restricted stock units.
Treace Medical Concepts, Inc. reported an insider ownership update for Chief Executive Officer and director John T. Treace. On January 10, 2026, a Form 4 lists a transaction in which 13,219 shares of common stock were disposed of at a price of $0.00 per share under transaction code F, leaving 6,775,887 common shares directly beneficially owned. This direct position includes 363,867 restricted stock units.
The filing also reports additional indirect holdings of common stock attributed to Mr. Treace’s spouse and various trusts, with share amounts of 1,605,000, 1,471,250, 1,839,063, and 408,816. The reporting person disclaims beneficial ownership of shares held by his wife directly or in trusts she controls, as well as shares held in trusts for which he serves as trustee or co‑trustee.